Anti-SLC34A2 (Lifastuzumab) -SPDB-DM4

Anti-SLC34A2 (Lifastuzumab) -SPDB-DM4 is an antibody-drug conjugate (ADC) consisting of the humanized anti-SLC34A2 (sodium-dependent phosphate transporter 2) antibody Lifastuzumab (HY-P99970) conjugated with the linker SPDB (HY-12448) and the tubulin inhibitor DM4 (HY-12454) . The ADC toxic molecule and linker part are sulfo-SPDB-DM4 (HY-101141) . Anti-SLC34A2 (Lifastuzumab) -SPDB-DM4 can be used in cancer research[1][2].

Product Specifications

UNSPSC

12352203

Target

Antibody-Drug Conjugates (ADCs) ; Microtubule/Tubulin; Sodium Channel

Related Pathways

Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage; Cytoskeleton; Membrane Transporter/Ion Channel

Applications

Cancer-programmed cell death

Field of Research

Cancer

Smiles

[Anti-SLC34A2(Lifastuzumab)-SPDB-DM4]

References & Citations

[1]Banerjee S, et al. Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study. Ann Oncol. 2018 Apr 1;29 (4) :917-923.|[2]Tang R, et al. P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients. BMC Cancer. 2009 Jun 23;9:199.